Найкращі онкологи з імунотерапії при раку легень в Туреччині – ТОП-21 лікар

Мустафа Солак, доктор медичних наук, є лікарем, який закінчив медичну школу Університету Хаджеттепе, пройшов ординатуру в навчально-дослідницькій лікарні Стамбула Шіслі Етфал і стипендію в Інституті раку Університету Хаджеттепе. Він спеціалізується на раку молочної залози, раку яєчок, раку яєчників, раку легенів, раку голови та шиї та раку шлунково-кишкового тракту. Він також працював у онкологічному центрі доктора медичних наук Андерсона Техаського університету, у навчальній лікарні Корум університету Хітіт та лікарні Медікал Парк.

Доктор Yesim Yıldırım є професором медичної онкології в Anadolu Medical Center і членом Європейського товариства медичної онкології (ESMO). Вона спеціалізується на імунотерапії та таргетній терапії раку, діагностиці та лікуванні злоякісних новоутворень і опублікувала понад 80 міжнародних і національних публікацій, тез і книг. Вона також має ступінь MBA з менеджменту охорони здоров’я та володіє англійською, російською та турецькою мовами.

Education and Career

2011 – 2015, (Internal Medicine Specialist) Istanbul University Istanbul School of Education and Career

Medicine Department of Internal Medicine

2015 – 2016, (Internal Medicine) Specialist Istanbul Haydarpasa Numune Training and Research Hospital

2016 – 2019, (Medical Oncology) Istanbul University Istanbul School of Medicine Department of Medical Oncology

2019 – 2021, (Medical Oncology Specialist) - Istanbul Haydarpasa Numune Training and Research Hospital

2021 – 2024, (Associate Professor) Marmara University School of Medicine Department of Medical Oncology

Memberships in Scientific Organizations

ASCO

ESMO

TTOD 

AVOD 

Publications

In the field of oncology, he has published over 30 peer-reviewed articles at both international and national levels.

Awards Received

EAACI The European Academy of Allergy and Clinical Immunology 2019 Best Poster Award

"The top 3rd verbal presentation, IGICC (11th International Gastrointestinal Cancers Conference – IGICC2021)"

Speeches Delivered at National Congresses, Conferences, and Symposia:

Courses, Meetings, and Certificates

ESMO certified Medical Oncologist since 2019

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

AREAS OF INTEREST

• Breast cancer
• Colon cancer
• Lung cancer
• Malignant melanoma
• Urogenital cancers
• Gynecological cancers
• Digestive system cancers

Education and Specialization

• 1987-1993 BSc Faculty of Medicine, Uludağ University Faculty of Medicine
• 1994-1999 BSc Internal Medicine Ondokuz Mayıs University Faculty of Medicine
• 2008-2011 PhD Medical Oncology Ankara Numune Training and Research Hospital
• 2016 Assoc. Prof. / Prof. Dr. Medical Oncology Okmeydanı Training and Research Hospital

Experience

• 1993-1994 General Practitioner Senirkent State Hospital Senirkent, Isparta
• 1994-1999 Research Position Ondokuz Mayıs University Faculty of Medicine Internal Medicine Department, Samsun
• 2000-2006 Specialist Doctor Diyarbakır SSK Hospital, Diyarbakır
• 2006-2008 Specialist Doctor Diyarbakır State Hospital, Diyarbakır
• 2008-2011 Dr. Minor Assistant Ankara Numune Training and Research Hospital
• 2011-2013 Specialist Doctor Diyarbakır Training and Research Hospital, Medical Oncology
• 2013- 2016 Specialist Doctor Okmeydanı Training and Research Hospital, Medical Oncology Clinic
• 2016 Education Manager Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Assoc. Prof.

Professional Memberships

Turkish Society of Medical Oncology

Education and Training:

• Medical Degree: Graduated from Uludağ University Faculty of Medicine in 1993.
• Specialization in Internal Medicine: Completed at Ondokuz Mayıs University Faculty of Medicine in 1999.
• Medical Oncology Fellowship: Completed at Ankara Numune Research and Training Hospital in 2011.
•  
• Professional Experience:
• Isparta Senirkent State Hospital: Completed his mandatory service as an Internal Medicine Specialist and Hemodialysis Responsible Physician (1993-1994).
• Prof. Dr. Gazi Yaşargil Training and Research Hospital: Served as a Medical Oncologist (2011-2013).
• Okmeydanı Research and Training Hospital: Achieved the title of Associate Professor and later full Professor, significantly contributing to medical oncology (2013-2016).
• Current Position: Professor of Medical Oncology at İstinye University Hospital Medical Park Gaziosmanpaşa, Istanbul, where he continues to provide top-tier oncology care and mentorship.

Areas of Expertise:

• Cancer Treatment: Specializes in the treatment of various cancers, including breast, colon, lung, malignant melanoma, urogenital, gynecological, and gastrointestinal cancers.
• Advanced Therapies: Proficient in administering chemotherapy, immunotherapy, and other cutting-edge treatments for cancer patients.
• Research and Education: Actively involved in cancer research and dedicated to educating the next generation of oncologists, continuously enhancing the field through both clinical practice and academic contributions.

• Extensive Experience:
•  
• With over 24 years of medical practice, Prof. Dr. Cihan is a highly respected figure in oncology, known for his comprehensive approach to cancer treatment.
• International Recognition: Participates in numerous international seminars and congresses, keeping abreast of the latest advancements in oncology.
• Patient-Centric Care: Renowned for his compassionate and personalized approach to patient care, ensuring tailored treatment plans that address the unique needs of each patient.
• Multidisciplinary Collaboration: Works with a multidisciplinary team of experts at Medical Park, providing holistic and coordinated care to achieve the best possible outcomes for patients.

Achievements and Awards:

• Academic Contributions: Has contributed significantly to oncology literature and research, with numerous publications in reputable medical journals.
• Leadership in Oncology: Recognized for his leadership in oncology, both in clinical settings and academic institutions, influencing cancer treatment practices and policies.

Онколог

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Досвідчений фахівець з медичної онкології з 11-річним стажем, який працював у різних медичних установах, включаючи медичний факультет Університету Памуккале, державну лікарню Хаккарі, навчальну та дослідницьку лікарню доктора Лютфі Кірдара Картала та державну лікарню Едірне Султан Мурат I. Член Турецької медичної онкологічної асоціації, Європейського товариства медичної онкології, Американського товариства клінічної онкології, Імуноонкологічної асоціації та Турецької медичної асоціації.

Доктор X має ступінь бакалавра медицини в Анкарі (1976), спеціалізацію з внутрішньої медицини в Анкарі (1981) і невелику спеціалізацію з медичної онкології в Стамбулі (1987). З 1986 року він обіймав різні посади в галузі онкології та внутрішньої медицини, а також є членом-засновником і активним членом різних онкологічних асоціацій і наукових організацій, таких як Турецька асоціація онкології, Асоціація медичної онкології, Асоціація хіміотерапії, Європейське товариство медичної онкології, Американське товариство клінічної онкології та Європейської асоціації клінічних досліджень раку.